Search

everythinglearnresearchcommunity

for

Search:↓

A 22-year-old with 4c hair is considering a hair transplant to address traction alopecia caused by braid extensions. They have tried derma stamping, oils, and minoxidil but stopped due to side effects.

The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.

CosmeRNA, a new hair loss treatment, is expected to release soon and may become part of the "big three" treatments alongside finasteride and minoxidil. It works differently from finasteride by targeting androgen receptors in hair follicles, potentially offering fewer side effects.

The user underwent a hair transplant 11 months ago and is satisfied with the results, regaining confidence. Post-operation treatments included oral minoxidil, finasteride, dutasteride, vitamin supplements, and occasional QR678 injections.

A 19-year-old shares positive results after one year on finasteride, minoxidil, micro-needling, and Nizoral shampoo, reporting no side effects and improved hair density despite initial shedding. Others discuss mixed experiences with finasteride, some considering alternatives like dutasteride or hair transplants.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.

A 40-year-old user shared their hair loss treatment progress since October 2023, using exosome treatment, minoxidil, finasteride, and microneedling. They started slacking on microneedling in February after stopping minoxidil.

The user is experiencing severe hair thinning and is using multiple treatments including topical finasteride, minoxidil, tretinoin, latanoprost, oral minoxidil, dutasteride, saw palmetto, and derma wounding. They are considering adding RU58841 and are contemplating a hair transplant and exosomes due to frustration with current results.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

The conversation discusses the potential of verteporfin in treating hair loss, with some users reporting positive results and speculating that it could lead to a cure for baldness. Others are skeptical, and there's a debate on the effectiveness of verteporfin for regrowing hair and reducing transplant scars.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

The user is experiencing hair thinning at the front of the scalp and is seeking advice on regrowing long curly hair. They are considering treatments like Minoxidil, finasteride, and RU58841 to prioritize hair regrowth.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

A 19-year-old has experienced worsening hair loss and thinning after using minoxidil and then finasteride, and has recently started dutasteride. They feel disappointed with the results and are seeking others' experiences for hope.

KX-826 may cause increased hair loss for some users, leading to concerns about its effects. One user reported no issues but also no hair regrowth, only maintenance.

Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

A 27-year-old male with AGA and diffused thinning has been using oral Minoxidil, Finasteride, Vitamin D, B12, Iron, and Ketoconazole shampoo. Despite a hair transplant and improved blood levels, he continues to experience hair loss and suspects a possible misdiagnosis of Alopecia Areata Incognita.

A 21-year-old shares their one-year progress using finasteride for hair loss, experiencing initial shedding but eventual regrowth, especially on the crown. They consider switching to dutasteride due to continued hair loss at the front temple and mid-scalp areas.

A user shared a 17-month update on their hair loss treatment, which included a hair transplant of 2300 grafts, using a topical solution of minoxidil and finasteride, a laser cap, and ketoconazole shampoo. They are considering another transplant and seeking honest feedback on their progress, while others share their own experiences and advice on hair loss treatments.

The conversation discusses the effectiveness of Vichy Dercos Aminexil Clinical R.E.G.E.N. Booster for hair shedding and thinning. The main ingredient, Aminexil, is compared to Minoxidil, and the user seeks real experiences to determine its efficacy.

KX-826 shows promising results for hair growth with fewer side effects, offering an alternative to finasteride and minoxidil. Users discuss combining it with minoxidil, dermarolling, and Nizoral for improved results.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

Pyrilutamide (KX826) sourcing and pricing, with users discussing the legitimacy and cost of grey market versus official sources. The conversation highlights the high cost of official products and the effectiveness of grey market versions.

A 19-year-old tried oral minoxidil and finasteride for hair loss but experienced side effects like fatigue, dry eyes, and lack of motivation, leading to discontinuation. Suggestions included trying topical treatments, dutasteride, or accepting hair loss.

The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.

A 17-year-old with thinning hair is considering using Revalid, a supplement with ingredients like biotin and zinc, based on parental recommendations. Another user suggests that supplements could help since the hair thinning doesn't seem to be androgenic alopecia.

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.